AR080680A1 - Proteinas de union a basigina - Google Patents
Proteinas de union a basiginaInfo
- Publication number
- AR080680A1 AR080680A1 ARP110100772A ARP110100772A AR080680A1 AR 080680 A1 AR080680 A1 AR 080680A1 AR P110100772 A ARP110100772 A AR P110100772A AR P110100772 A ARP110100772 A AR P110100772A AR 080680 A1 AR080680 A1 AR 080680A1
- Authority
- AR
- Argentina
- Prior art keywords
- basigin
- antibodies
- union
- proteins
- union proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticuerpos, que se unen a la basigina (BSG), por ejemplo, la BSG2 humana, y composiciones y moléculas basadas en anticuerpos relacionadas. También se divulgan composiciones farmacéuticas que comprenden los anticuerpos, así como métodos terapéuticos y de diagnostico para el uso de los anticuerpos. Ácidos nucleicos, vector, célula huésped e hibridona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31293210P | 2010-03-11 | 2010-03-11 | |
US36356010P | 2010-07-12 | 2010-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080680A1 true AR080680A1 (es) | 2012-05-02 |
Family
ID=44560208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100772A AR080680A1 (es) | 2010-03-11 | 2011-03-11 | Proteinas de union a basigina |
Country Status (5)
Country | Link |
---|---|
US (1) | US20110223176A1 (es) |
AR (1) | AR080680A1 (es) |
TW (1) | TW201134489A (es) |
UY (1) | UY33274A (es) |
WO (1) | WO2011112566A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2794652B1 (en) * | 2011-12-21 | 2017-11-15 | F. Hoffmann-La Roche AG | Rapid method for cloning and expression of cognate antibody variable region gene segments |
US9816989B2 (en) | 2013-03-12 | 2017-11-14 | Institute of Arthritis Research, LLC | Immunologically active polypeptide |
CN109072229A (zh) * | 2016-04-06 | 2018-12-21 | 定制药品研究株式会社 | 使用了抗mct5抗体的癌症治疗用药物组合物 |
CN105820250B (zh) * | 2016-04-29 | 2019-04-30 | 中国人民解放军第四军医大学 | 一种抗basigin人源化抗体及其应用 |
CN108261544B (zh) * | 2016-12-30 | 2023-05-05 | 江苏太平洋美诺克生物药业股份有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
CN108261391B (zh) * | 2016-12-30 | 2022-03-01 | 江苏太平洋美诺克生物药业有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
KR20190134654A (ko) * | 2017-03-09 | 2019-12-04 | 싸이톰스 테라퓨틱스, 인크. | Cd147 항체, 활성화가능한 cd147 항체, 그리고 이를 만들고, 이용하는 방법 |
BR112020016005A2 (pt) | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio |
CN110674726A (zh) * | 2019-09-20 | 2020-01-10 | 清华大学 | 基于目标检测与迁移学习的皮肤病辅助诊断方法及*** |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010034554A (ko) * | 1998-03-03 | 2001-04-25 | 레이몬드, 엠. 위티 | 치료제로서의 cd147 결합 분자 |
US20050026215A1 (en) * | 2003-07-17 | 2005-02-03 | Predki Paul F. | Method for the prediction of an epitope |
US7241598B2 (en) * | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
EP1784425A4 (en) * | 2004-06-30 | 2009-02-18 | Centocor Inc | ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
EP3002299A1 (en) * | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
-
2011
- 2011-03-08 WO PCT/US2011/027521 patent/WO2011112566A2/en active Application Filing
- 2011-03-08 US US13/042,650 patent/US20110223176A1/en not_active Abandoned
- 2011-03-11 TW TW100108413A patent/TW201134489A/zh unknown
- 2011-03-11 AR ARP110100772A patent/AR080680A1/es not_active Application Discontinuation
- 2011-03-11 UY UY0001033274A patent/UY33274A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY33274A (es) | 2011-09-30 |
WO2011112566A3 (en) | 2011-10-27 |
TW201134489A (en) | 2011-10-16 |
US20110223176A1 (en) | 2011-09-15 |
WO2011112566A2 (en) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080680A1 (es) | Proteinas de union a basigina | |
AR114031A2 (es) | Moléculas de unión a 4-1bb | |
UY32971A (es) | Proteínas de unión al antígeno de la il-23 humana | |
BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
UY35456A (es) | Moléculas de unión para bcma y cd3 | |
CY1121466T1 (el) | Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης | |
CL2013000369A1 (es) | Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer. | |
ECSP13012794A (es) | Anticuerpos anti-cd38 | |
BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
MX2015011830A (es) | Metodos de fabricacion y sintesis de grupos de enlace de aminoacidos conjugados con compuestos usados para la obtencion de imagenes dirigida de los tumores. | |
PE20151613A1 (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
PE20190229A1 (es) | Anticuerpos anti-fcrn | |
AR079551A1 (es) | Anticuerpos anti-her3 y usos de los mismos | |
CL2012000524A1 (es) | Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. | |
AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
AR090884A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
AR089752A1 (es) | Anticuerpos anti-lrp5 y metodos de uso | |
CL2009000862A1 (es) | Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer. | |
CR20130662A (es) | Anticuerpos a adp-ribosil ciclasa 2 | |
BR112018005464A2 (pt) | expressão de proteínas contendo fc | |
AR121799A2 (es) | Proteínas de unión a antígenos de il-23 humana | |
AR103294A1 (es) | Composiciones y procedimientos para la glicosilación de proteínas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |